Drug Development for CFS and ME: Public Workshop to be held April 25/26, 2013
The registration deadline is fast approaching. Monday April 8th, 2013 (5pm eastern time) is the deadline for:
registration to attend,
registering to view the webcast,
consideration for participation on Day 1 panels,
public comment summaries.
Register here: http://mecfsmeeting.eventbrite.com/#
You can request to be part of a Day 1 panel discussion (topics below)
Suggestions for those providing comments: For those who wish to provide comments, either as part of the panel or as part of the ‘open discussion’, the following information will be useful:
- The suggested topics include:
- Topic 1: Disease Symptoms and Daily Impacts That Matter Most to Patients
- Topic 2: Patients’ Perspectives on Current Approaches To Treating CFS and M
The questions that the FDA is asking on each of these topics are listed below. You are also given the option to suggest a topic when you register.
- In addition to the questions that the FDA asked, please provide comments about your lab/test abnormalities – linked to symptoms and dysfunction where possible – and indicate how those abnormalities changed as a result of treatment if known.
If you wish to be considered to present comments part of initial panel discussions, you will need to indicate the topic that you wish to address when you register. Then, you will need to send a brief summary of your response to the topic(s) you selected to ME-CFS-Meeting@fda.hhs.gov. The deadline to send the summary of your comments is April 8. You will be notified before the meeting if you will be on a panel.
You can request to provide comments on other topics as part of the open comment period at the end of the day
If you want to do this, you will need to register as above. In addition, you will need to send a brief summary of your comments for the open public comment session to ME-CFS-Meeting@fda.hhs.gov. The deadline to submit the summary of your comments is April 8.
Previously we had heard that public comment by proxy would be allowed. This is no longer the case as apparently there are so many community members who want to provide comment in person that FDA can only schedule those providing comment in person. BUT everyone can submit comments to the docket.
Provide comments directly to the FDA now
- Go here and submit comments now by clicking on the ‘Comment Now!” box in the upper right corner of the page.
- You can also submit written comments to Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Include the docket number, which is “FDA-2012-N-0962-0004”.
- The Docket is open until August 2, 2013.
-
The FDA is encouraging patients to provide answers to the questions asked in the Federal Register. But again, don’t forget to also include information about the biological abnormalities – linked to symptoms where possible – and indicate how those abnormalities changed as a result of treatment if known.
Participate in the FDA meeting remotely
Remember to respond to two different surveys that are collecting information for the meeting.
- Both surveys are collecting information a) disease symptoms and daily impacts that matter most to patients and b) patient perspectives on current approaches to treating ME/CFS.
- Dr. Leonard Jason and his team and Dr. Lily Chu have created an online survey that uses checkboxes to collect information on symptoms, impact on daily life, treatments being used and the effect of treatments. For those who live outside the U.S., ignore questions about the U.S. region. The link to Dr. Jason’s and Dr. Chu’s survey is here.
- The CFIDS Association of America (CAA) has taken the questions from the FDA workshop agenda and turned them into an online questionnaire where you can type answers into text boxes. The link to the survey is here.
- Both surveys are open to everyone no matter where you live. Your responses will be anonymous and confidential.
- Please try to answer both questionnaires.
- Although the surveys may not ask for it specifically, don’t forget to also include comments as above about your lab abnormalities – linked to symptoms and disease dysfunction where possible – and indicate how those abnormalities changed as a result of treatment if known. Examples are given above in #1.
Register for CFSAC May 2013 attendance and for public comment
Published April 30, 2013 Uncategorized Leave a CommentTags: advocacy, CFSAC, chronic fatigue syndrome, DHHS, early onset ME/CFS, government, health, ME/CFS, participate, participation, public comment, registration, research, science, upcoming events, Washington
The Spring 2013 CFSAC meeting will be held May 22–23, 2013
Registration is open:
http://www.blsmeetings.net/CFSACMay2013/
To register for public comment:
http://www.blsmeetings.net/CFSACPublicCommentMay2013/
The Federal Register notice for the May 2013 CFSAC meeting:
http://www.gpo.gov/fdsys/pkg/FR-2013-04-30/pdf/2013-10083.pdf
The meeting will be held at the Department of Health and Human Services; Hubert H. Humphrey Building; 200 Independence Avenue SW., Room 800; Washington, DC 2020
Share this: